{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:32:11Z","timestamp":1792038731456,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T00:00:00Z","timestamp":1740614400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA133049"],"award-info":[{"award-number":["R01CA133049"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10549-025-07644-3","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T20:11:30Z","timestamp":1740600690000},"page":"261-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The impact of coadministration\u00a0of venlafaxine, citalopram or gabapentin on the metabolic activation of tamoxifen"],"prefix":"10.1007","volume":"211","author":[{"given":"Stephanie L.","family":"Safgren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera J.","family":"Suman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto A.","family":"Leon Ferre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew L.","family":"Kosel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vered","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. Lynn","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelima","family":"Denduluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Irvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James N.","family":"Ingle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kostantinos","family":"Sideras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew M.","family":"Ames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John L.","family":"Black","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Weinshilboum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,27]]},"reference":[{"issue":"1","key":"7644_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 23","key":"7644_CR2","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1002\/cncr.29059","volume":"120","author":"N Howlader","year":"2014","unstructured":"Howlader N, Chen VW, Ries LA, Loch MM, Lee R, DeSantis C, Lin CC, Ruhl J, Cronin KA (2014) Overview of breast cancer collaborative stage data items \u2013 their definitions, quality, usage, and clinical implications: a review of SEER data for 2004\u20132010. Cancer 120(Suppl 23):3771\u20133780. https:\/\/doi.org\/10.1002\/cncr.29059","journal-title":"Cancer"},{"issue":"9472","key":"7644_CR3","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"EBCTCG","year":"2005","unstructured":"EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687\u20131717. https:\/\/doi.org\/10.1016\/S0140-6736(05)66544-0","journal-title":"Lancet"},{"issue":"18","key":"7644_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1093\/jnci\/90.18.1371","volume":"90","author":"B Fisher","year":"1998","unstructured":"Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90(18):1371\u20131388","journal-title":"J Natl Cancer Inst"},{"issue":"9122","key":"7644_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/s0140-6736(98)85012-5","volume":"352","author":"T Powles","year":"1998","unstructured":"Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352(9122):98\u2013101. https:\/\/doi.org\/10.1016\/s0140-6736(98)85012-5","journal-title":"Lancet"},{"issue":"9247","key":"7644_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/s0140-6736(00)03403-6","volume":"356","author":"CL Loprinzi","year":"2000","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ (2000) Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 356(9247):2059\u20132063. https:\/\/doi.org\/10.1016\/s0140-6736(00)03403-6","journal-title":"Lancet"},{"issue":"6","key":"7644_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1200\/JCO.2002.20.6.1578","volume":"20","author":"CL Loprinzi","year":"2002","unstructured":"Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novotny PJ, Rummans TA (2002) Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20(6):1578\u20131583","journal-title":"J Clin Oncol"},{"issue":"17","key":"7644_CR8","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1200\/JCO.2008.19.6253","volume":"27","author":"CL Loprinzi","year":"2009","unstructured":"Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T Jr, Barton D, Novotny P (2009) Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 27(17):2831\u20132837. https:\/\/doi.org\/10.1200\/JCO.2008.19.6253","journal-title":"J Clin Oncol"},{"issue":"29","key":"7644_CR9","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1200\/jco.2010.33.1298","volume":"29","author":"AH Boekhout","year":"2011","unstructured":"Boekhout AH, Vincent AD, Dalesio OB, van den Bosch J, Foekema-T\u00f6ns JH, Adriaansz S, Sprangers S, Nuijen B, Beijnen JH, Schellens JH (2011) Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 29(29):3862\u20133868. https:\/\/doi.org\/10.1200\/jco.2010.33.1298","journal-title":"J Clin Oncol"},{"issue":"2","key":"7644_CR10","doi-asserted-by":"publisher","first-page":"172.e1","DOI":"10.1016\/j.ajog.2008.09.877","volume":"200","author":"DF Archer","year":"2009","unstructured":"Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S (2009) A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 200(2):172.e1-172.e10. https:\/\/doi.org\/10.1016\/j.ajog.2008.09.877","journal-title":"Am J Obstet Gynecol"},{"issue":"21","key":"7644_CR11","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1001\/jama.289.21.2827","volume":"289","author":"V Stearns","year":"2003","unstructured":"Stearns V, Beebe KL, Iyengar M, Dube E (2003) Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 289(21):2827\u20132834. https:\/\/doi.org\/10.1001\/jama.289.21.2827","journal-title":"JAMA"},{"issue":"1","key":"7644_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/00042192-200512010-00006","volume":"12","author":"E Suvanto-Luukkonen","year":"2005","unstructured":"Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, Tapanainen JS (2005) Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause Jan-Feb 12(1):18\u201326","journal-title":"Menopause Jan-Feb"},{"issue":"4","key":"7644_CR13","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/01.gme.0000196595.82452.ca","volume":"13","author":"PR Gordon","year":"2006","unstructured":"Gordon PR, Kerwin JP, Boesen KG, Senf J (2006) Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 13(4):568\u2013575. https:\/\/doi.org\/10.1097\/01.gme.0000196595.82452.ca","journal-title":"Menopause"},{"issue":"20","key":"7644_CR14","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1200\/JCO.2009.26.6379","volume":"28","author":"DL Barton","year":"2010","unstructured":"Barton DL, LaVasseur BI, Sloan JA, Stawis AN, Flynn KA, Dyar M, Johnson DB, Atherton PJ, Diekmann B, Loprinzi CL (2010) Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 28(20):3278\u20133283. https:\/\/doi.org\/10.1200\/JCO.2009.26.6379","journal-title":"J Clin Oncol"},{"issue":"2","key":"7644_CR15","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1075-122X.2006.00218.x","volume":"12","author":"GG Kimmick","year":"2006","unstructured":"Kimmick GG, Lovato J, McQuellon R, Robinson E, Muss HB (2006) Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 12(2):114\u2013122. https:\/\/doi.org\/10.1111\/j.1075-122X.2006.00218.x","journal-title":"Breast J"},{"issue":"9488","key":"7644_CR16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/S0140-6736(05)67215-7","volume":"366","author":"KJ Pandya","year":"2005","unstructured":"Pandya KJ, Morrow GR, Roscoe JA, Zhao H, Hickok JT, Pajon E, Sweeney TJ, Banerjee TK, Flynn PJ (2005) Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 366(9488):818\u2013824. https:\/\/doi.org\/10.1016\/S0140-6736(05)67215-7","journal-title":"Lancet"},{"issue":"3","key":"7644_CR17","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1200\/JCO.2006.07.5390","volume":"25","author":"CL Loprinzi","year":"2007","unstructured":"Loprinzi CL, Kugler JW, Barton DL, Dueck AC, Tschetter LK, Nelimark RA, Balcueva EP, Burger KN, Novotny PJ, Carlson MD, Duane SF, Corso SW, Johnson DB, Jaslowski AJ (2007) Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. J Clin Oncol 25(3):308\u2013312. https:\/\/doi.org\/10.1200\/JCO.2006.07.5390","journal-title":"J Clin Oncol"},{"key":"7644_CR18","unstructured":"Pratt LA, Brody DJ, Gu Q (2011) Antidepressant use in persons aged 12 and over: United States, 2005\u20132008. NCHS data brief, no 76 Hyattsville: National Center for Health Statistics"},{"issue":"1","key":"7644_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1389200023338017","volume":"3","author":"A Hemeryck","year":"2002","unstructured":"Hemeryck A, Belpaire FM (2002) Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 3(1):13\u201337","journal-title":"Curr Drug Metab"},{"issue":"1","key":"7644_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97(1):30\u201339. https:\/\/doi.org\/10.1093\/jnci\/dji005","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"7644_CR21","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1158\/0008-5472.CAN-08-3933","volume":"69","author":"X Wu","year":"2009","unstructured":"Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC (2009) The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 69(5):1722\u20131727. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3933","journal-title":"Cancer Res"},{"issue":"2","key":"7644_CR22","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/sj.clpt.6100406","volume":"83","author":"A Gaedigk","year":"2008","unstructured":"Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS (2008) The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83(2):234\u2013242. https:\/\/doi.org\/10.1038\/sj.clpt.6100406","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"7644_CR23","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jmoldx.2016.01.003","volume":"18","author":"Y Ji","year":"2016","unstructured":"Ji Y, Skierka JM, Blommel JH, Moore BE, VanCuyk DL, Bruflat JK, Peterson LM, Veldhuizen TL, Fadra N, Peterson SE, Lagerstedt SA, Train LJ, Baudhuin LM, Klee EW, Ferber MJ, Bielinski SJ, Caraballo PJ, Weinshilboum RM, Black JL 3rd (2016) Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J Mol Diagn 18(3):438\u2013445. https:\/\/doi.org\/10.1016\/j.jmoldx.2016.01.003","journal-title":"J Mol Diagn"},{"issue":"23","key":"7644_CR24","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA (2003) Active tamoxifen metabolite plasma concentrations after co-administration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95(23):1758\u20131764","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"7644_CR25","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE Murdter","year":"2011","unstructured":"Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, Eichelbaum M, Schwab M, Brauch H (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 89(5):708\u2013717. https:\/\/doi.org\/10.1038\/clpt.2011.27","journal-title":"Clin Pharmacol Ther"},{"issue":"36","key":"7644_CR26","doi-asserted-by":"publisher","first-page":"9312","DOI":"10.1200\/JCO.2005.03.3266","volume":"23","author":"MP Goetz","year":"2005","unstructured":"Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23(36):9312\u20139318. https:\/\/doi.org\/10.1200\/JCO.2005.03.3266","journal-title":"J Clin Oncol"},{"issue":"4","key":"7644_CR27","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/tpj.2009.14","volume":"9","author":"JM Rae","year":"2009","unstructured":"Rae JM, Sikora MJ, Henry NL, Li L, Kim S, Oesterreich S, Skaar TC, Nguyen AT, Desta Z, Storniolo AM, Flockhart DA, Hayes DF, Stearns V (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9(4):258\u2013264. https:\/\/doi.org\/10.1038\/tpj.2009.14","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"7644_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/tpj.2014.34","volume":"15","author":"P Saladores","year":"2015","unstructured":"Saladores P, Murdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, Ganchev B, Eccles B, Gerty S, Tfayli A, Lim JS, Yap YS, Ng RC, Wong NS, Dent R, Habbal MZ, Schaeffeler E, Eichelbaum M, Schroth W, Schwab M, Brauch H (2015) Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J 15(1):84\u201394. https:\/\/doi.org\/10.1038\/tpj.2014.34","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"7644_CR29","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP (2011) Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 89(5):718\u2013725. https:\/\/doi.org\/10.1038\/clpt.2011.32","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"7644_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA (2006) Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 80(1):61\u201374. https:\/\/doi.org\/10.1016\/j.clpt.2006.03.013","journal-title":"Clin Pharmacol Ther"},{"issue":"16","key":"7644_CR31","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.2009.23.8931","volume":"28","author":"K Sideras","year":"2010","unstructured":"Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, Black JL, Weinshilboum RM, Hawse JR, Spelsberg TC, Goetz MP (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28(16):2768\u20132776. https:\/\/doi.org\/10.1200\/JCO.2009.23.8931","journal-title":"J Clin Oncol"},{"issue":"1","key":"7644_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1111\/cts.12692","volume":"13","author":"KE Caudle","year":"2020","unstructured":"Caudle KE, Sangkuhl K, Whirl-Carrillo M, Swen JJ, Haidar CE, Klein TE, Gammal RS, Relling MV, Scott SA, Hertz DL, Guchelaar HJ, Gaedigk A (2020) Standardizing CYP2D6 genotype to phenotype translation: consensus recommendations from the clinical pharmacogenetics implementation consortium and Dutch pharmacogenetics working group. Clin Transl Sci 13(1):116\u2013124. https:\/\/doi.org\/10.1111\/cts.12692","journal-title":"Clin Transl Sci"},{"issue":"1\u20132","key":"7644_CR33","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S1570-0232(03)00218-6","volume":"791","author":"KH Lee","year":"2003","unstructured":"Lee KH, Ward BA, Desta Z, Flockhart DA, Jones DR (2003) Quantification of tamoxifen and three metabolites in plasma by high-performance liquid chromatography with fluorescence detection: application to a clinical trial. J Chromatogr B Analyt Technol Biomed Life Sci 791(1\u20132):245\u2013253","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"13","key":"7644_CR34","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302(13):1429\u20131436. https:\/\/doi.org\/10.1001\/jama.2009.1420","journal-title":"JAMA"},{"key":"7644_CR35","unstructured":"Yasaei R, Katta S, Patel P, Saadabadi A (2024) Gabapentin. StatPearls"},{"issue":"3","key":"7644_CR36","doi-asserted-by":"publisher","first-page":"324","DOI":"10.6004\/jnccn.2016.0037","volume":"14","author":"WJ Gradishar","year":"2016","unstructured":"Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R (2016) Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(3):324\u2013354","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"7644_CR37","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s10549-013-2565-3","volume":"139","author":"J Karle","year":"2013","unstructured":"Karle J, Bolbrinker J, Vogl S, Kreutz R, Denkert C, Eucker J, Wischnewsky M, Possinger K, Regierer AC (2013) Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer. Breast Cancer Res Treat 139(2):553\u2013560. https:\/\/doi.org\/10.1007\/s10549-013-2565-3","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"7644_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10549-008-0272-2","volume":"118","author":"MJ Bijl","year":"2009","unstructured":"Bijl MJ, van Schaik RH, Lammers LA, Hofman A, Vulto AG, van Gelder T, Stricker BH, Visser LE (2009) The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users. Breast Cancer Res Treat 118(1):125\u2013130. https:\/\/doi.org\/10.1007\/s10549-008-0272-2","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"7644_CR39","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1038\/sj.bjc.6605800","volume":"103","author":"LA Lammers","year":"2010","unstructured":"Lammers LA, Mathijssen RH, van Gelder T, Bijl MJ, de Graan AJ, Seynaeve C, van Fessem MA, Berns EM, Vulto AG, van Schaik RH (2010) The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br J Cancer 103(6):765\u2013771. https:\/\/doi.org\/10.1038\/sj.bjc.6605800","journal-title":"Br J Cancer"},{"issue":"3","key":"7644_CR40","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/jpet.104.065607","volume":"310","author":"Z Desta","year":"2004","unstructured":"Desta Z, Ward BA, Soukhova NV, Flockhart DA (2004) Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 310(3):1062\u20131075. https:\/\/doi.org\/10.1124\/jpet.104.065607","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"7644_CR41","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/s0006-2952(96)00650-8","volume":"53","author":"HK Crewe","year":"1997","unstructured":"Crewe HK, Ellis SW, Lennard MS, Tucker GT (1997) Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 53(2):171\u2013178. https:\/\/doi.org\/10.1016\/s0006-2952(96)00650-8","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"7644_CR42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1159\/000028333","volume":"59","author":"OV Olesen","year":"1999","unstructured":"Olesen OV, Linnet K (1999) Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology 59(6):298\u2013309. https:\/\/doi.org\/10.1159\/000028333","journal-title":"Pharmacology"},{"issue":"6","key":"7644_CR43","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/s0006-3223(98)00353-9","volume":"46","author":"LL von Moltke","year":"1999","unstructured":"von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Duan SX, Fogelman SM, Harmatz JS, Shader RI (1999) Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biol Psychiatry 46(6):839\u2013849. https:\/\/doi.org\/10.1016\/s0006-3223(98)00353-9","journal-title":"Biol Psychiatry"},{"issue":"1","key":"7644_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00008571-199702000-00001","volume":"7","author":"B Rochat","year":"1997","unstructured":"Rochat B, Amey M, Gillet M, Meyer UA, Baumann P (1997) Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 7(1):1\u201310. https:\/\/doi.org\/10.1097\/00008571-199702000-00001","journal-title":"Pharmacogenetics"},{"issue":"5","key":"7644_CR45","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/S0893-133X(98)00113-4","volume":"20","author":"SM Fogelman","year":"1999","unstructured":"Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20(5):480\u2013490. https:\/\/doi.org\/10.1016\/S0893-133X(98)00113-4","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"7644_CR46","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/j.1365-2125.1996.tb00173.x","volume":"41","author":"SV Otton","year":"1996","unstructured":"Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM (1996) Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 41(2):149\u2013156. https:\/\/doi.org\/10.1111\/j.1365-2125.1996.tb00173.x","journal-title":"Br J Clin Pharmacol"},{"key":"7644_CR47","unstructured":"Pfizer Neurontin (gabepentin) [package insert] (2017, Oct). FDA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/020235s064_020882s047_021129s046lbl.pdf. Accessed June 2023"},{"key":"7644_CR48","doi-asserted-by":"publisher","first-page":"OF1","DOI":"10.1158\/1055-9965.EPI-24-0755","volume":"34","author":"RF MacLehose","year":"2024","unstructured":"MacLehose RF, Ahern TP, Collin LJ, Li A, Lash TL (2024) CYP2D6 phenotype and breast cancer outcomes: a bias analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev 34:OF1\u2013OF10. https:\/\/doi.org\/10.1158\/1055-9965.EPI-24-0755","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07644-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07644-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T22:06:41Z","timestamp":1743372401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07644-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["7644"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07644-3","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.P.G. reports personal fees for CME activities from Research to Practice, Clinical Education Alliance, Medscape, and MJH Life Sciences; personal fees serving as a panelist for a panel discussion from Total Health Conferencing and Ideology, and personal fees for serving as a moderator for Curio Science,  Consulting fees to Mayo Clinic from ARC Therapeutics, AstraZeneca, Biotheranostics, Blueprint Medicines, Lilly, Rna Diagnostics, Sanofi Genzyme, Seattle Genetics and Engage Health Media; and grant funding to Mayo Clinic from Lilly, Pfizer, Sermonix, Loxo, AstraZeneca, ATOSSA and Takeda.  N.L.H has personal fees for consulting with AstraZeneca, and for royalties from Up-to-Date. R.M.W is a cofounder and stockholder in OneOme LLC.  V.S. received research grants to institution from Abbvie, Biocept, Novartis, Pfizer, Puma Biotechnology, and QUE Oncology, is the Chair, Data Safety Monitoring Board, AstraZeneca and receives non-financial support from Foundation Medicine Study Assays.  The remaining authors declared no competing interests for this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}